Novavax Inc NVAX shares are trading higher Tuesday after the company announced the World Health Organization (WHO) issued an updated Emergency Use Listing for its Nuvaxovid vaccine as a primary series in adolescents and as a booster in adults.
The updated listing was based on data from an ongoing pediatric expansion of the Phase 3 PREVENT-19 trial. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall.
The primary series for adolescents aged 12 through 17 will be delivered as a series of two Nuvaxovid doses.
The updated listing for Nuvaxovid as a booster in adults aged 18 and older is supported by data from Novavax' two Phase 2 trials and a COV-BOOST trial. In the COV-BOOST trial, Nuvaxovid induced a meaningful antibody response when used as a heterologous third booster dose.
The WHO previously granted Emergency Use Listing for Nuvaxovid in adults aged 18 and older in December 2021.
NVAX Price Action: Novavax has a 52-week high of $236.50 and a 52-week low of $16.
The stock was up 3% at $17.15 at time of publication, according to Benzinga Pro.
Photo: Jernej Furman from Flickr.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.